Sialylated HMO Outlook: Microbial Fermentation Production Shifting from Import Dependence to Domestic Supply

Introduction: Bridging the Gap Between Breast Milk and Infant Formula with Bioactive Oligosaccharides
Infant formula developers, pediatric nutrition scientists, and early-life health researchers face a persistent formulation gap: human milk contains a complex array of human milk oligosaccharides (HMOs) that selectively shape the infant gut microbiome, support immune system maturation, and protect against enteric pathogens. Conventional infant formula lacks these bioactive compounds, resulting in a gut microbiota composition distinct from breastfed infants (lower Bifidobacterium abundance, higher pathogenic potential). The solution lies in sialylated human milk oligosaccharides (HMO) —acidic oligosaccharides formed by sialic acid (N-acetylneuraminic acid, Neu5Ac) linked to lactose (or longer core structures). Sialylated HMOs are an important type of HMOs, accounting for approximately 13% of total HMOs. 3‘-Sialyllactose (3‘-SL) and 6‘-sialyllactose (6‘-SL) are the two simplest sialylated HMOs, serving as key functional ingredients in premium infant formula. This report provides a comprehensive forecast of adoption trends, isomeric type segmentation, production technology evolution, and regulatory dynamics through 2032.

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sialylated Human Milk Oligosaccharides (HMO) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sialylated Human Milk Oligosaccharides (HMO) market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Sialylated Human Milk Oligosaccharides (HMO) was estimated to be worth US153millionin2025andisprojectedtoreachUS153millionin2025andisprojectedtoreachUS 438 million by 2032, growing at a CAGR of 16.5% from 2026 to 2032. In 2025, global production reached approximately 802 metric tons, with an average global market price of around US191perkilogram(approximatelyUS191perkilogram(approximatelyUS 191,000 per ton). This updated valuation (Q2 2026 data) reflects the sector‘s transition from basic supplementation toward specialized functional nutrition, driven by synthetic biology breakthroughs and expanding regulatory approvals.

Market Dynamics & Production Landscape
The global market for sialylated Human Milk Oligosaccharides (HMOs) is shifting from basic supplementation toward specialized functional nutrition. Synthetic biology breakthroughs have established microbial fermentation (engineered E. coli, yeast (Pichia pastoris), Bacillus subtilis) as the dominant production route (replacing chemical synthesis, enzymatic synthesis from natural sources), with domestic pioneers (China) achieving commercial production of synthetic HMO products and breaking previous import dependency (Europe, Japan, US).

Kyowa Hakko Bio (Japan) completed an HMO production facility in Thailand in 2022 and began commercial production there; in 2023 it received FDA no-question letters covering 3‘-SL and 6‘-SL for non-exempt infant formula (GRAS Notice) and conventional foods, and in 2024 its 3‘-SL and 6‘-SL were already within the EU novel-food authorization framework (EFSA safety assessment positive), indicating that major-market access is opening for Asian manufacturers beyond European incumbents (Novonesis, Inbiose/dsm-firmenich, Glycom/dsm-firmenich). As a result, competition is shifting from simple capacity expansion to quality standards (purity >95%, >98%, >99%), regulatory capability (FDA GRAS, EFSA Novel Food, China NHC, FSANZ, Health Canada, Japan FOSHU), and supply reliability (consistency, traceability, contamination control, heavy metal limits).

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5771887/sialylated-human-milk-oligosaccharides–hmo

Technical Classification & Product Segmentation

The Sialylated Human Milk Oligosaccharides (HMO) market is segmented as below:

Segment by Isomer Type

• 3‘-Sialyllactose (3‘-SL) – Sialic acid (Neu5Ac) linked α2,3 to galactose. Predominant sialylated HMO in human milk (higher abundance). Preferred by Bifidobacterium longum subsp. infantis (possesses specific α2,3-sialidase for utilization). Market share (volume): 55-60%.
• 6‘-Sialyllactose (6‘-SL) – Sialic acid linked α2,6 to galactose. Lower abundance in human milk. Utilized by Bifidobacterium bifidum, Bifidobacterium breve. Distinct immunomodulatory properties. Market share: 40-45%.

Segment by End-Use Application

• Infant Formula – Stage 1 (0-6 months), Stage 2 (6-12 months), follow-on formula, specialty formula (preterm, low birth weight, cow‘s milk protein allergy). Largest segment (70-75% of demand).
• Food – Functional foods (yogurt, dairy drinks, cereals, snacks), dietary supplements (capsules, powders, gummies), medical foods (enteral nutrition, oral nutritional supplements). 15-20%.
• Others – Cosmeceuticals (skin health, anti-aging), veterinary (pet probiotics, companion animal gut health), research reagents. 5-10%.

Key Players & Competitive Landscape

• Novonesis (Denmark) – Global leader (Novozymes/Chr. Hansen merger). 3‘-SL, 6‘-SL via fermentation. FDA GRAS, EFSA Novel Food, China NHC approvals. Supplies major infant formula brands (Nestlé, Danone, Abbott, Reckitt).
• Inbiose (dsm-firmenich) (Belgium/Netherlands) – 3‘-SL, 6‘-SL via fermentation. Part of dsm-firmenich HMO portfolio. European leader.
• DSM (Glycom A/S) (Netherlands/Denmark) – Acquired by dsm-firmenich (2021). 3‘-SL, 6‘-SL via fermentation. European pioneer.
• Kyowa Hakko Bio (Japan) – 3‘-SL, 6‘-SL via enzymatic synthesis (sialyltransferase). Thailand facility operational (2022). FDA GRAS (2023), EU Novel Food authorization (2024). Asian supply for Japan, China, Southeast Asia.
• GeneChem Inc. – South Korean biotech.
• Elicityl (France) – R&D scale HMOs (research reagents, small-scale). Not industrial.
• Zhuhai Langjian Biotechnology (China) – Chinese 3‘-SL manufacturer via fermentation. Received China NHC approval (2026, 3‘-SL sodium salt for infant formula). Domestic supply.
• Shanghai HuicH Biotech (China) – Chinese 3‘-SL, 6‘-SL R&D, pilot scale. Emerging.

Recent Industry Developments (Last 6 Months – March to September 2026)

• May 2026: China National Health Commission (NHC) approved 3‘-sialyllactose (3‘-SL) sodium salt as novel food ingredient for infant formula (effective May 2026). Permitted up to 200 mg/L (reconstituted formula) for 0-12 months. Follows 2‘-FL (fucosyllactose) and LNnT approvals (2022, 2023). Chinese domestic manufacturers (Zhuhai Langjian, Shanghai HuicH) first to market domestic HMO, reducing reliance on Novonesis, Inbiose, DSM, Kyowa Hakko.
• June 2026: Kyowa Hakko Bio (Thailand facility) expanded 6‘-SL production capacity (new fermenters, downstream purification, drying). Targets Chinese infant formula market (via NHC authorization application for 6‘-SL pending), Southeast Asia (growing HMO demand). Kyowa uses enzymatic synthesis: sialyltransferase (ST) converts CMP-sialic acid (CMP-Neu5Ac) and lactose to sialyllactose, differentiates from fermentation-based competitors (claims higher purity, lower endotoxin, less byproduct). Regulatory submissions in progress.
• Technical challenge identified by QYResearch field surveys (August 2026): Purity specifications (95% vs. 98% vs. 99%) critical for infant formula safety and regulatory compliance. Field data from 800 tons of sialylated HMO production (2025-2026, multiple manufacturers):
  • 95% purity (food grade) : acceptable for general foods (yogurt, beverages, supplements). Contains residual lactose, salts, monosaccharides, organic acids. Lower cost ($100-150/kg).
  • 98% purity (infant formula grade) : required for infant formula (regulatory specification, GB 10765, EU Directive 2006/141). Removes >98% of impurities. Higher production cost (extra polishing, chromatography, ultrafiltration, crystallization).
  • 99% purity (pharma grade) : for clinical nutrition, medical foods, research. Very high purity (<1% impurities). Highest cost.
  • Competition shifting to reliability of meeting 98% purity for infant formula (batch-to-batch consistency, avoiding supply disruption). Novonesis, Inbiose, DSM, Kyowa Hakko, Zhuhai Langjian, Shanghai HuicH capability.

Key Industry Dynamics: From Basic Supplementation to Specialized Functional Nutrition

Exclusive Observation: “Complex Sialylated HMOs (Beyond 3‘-SL and 6‘-SL) – Next Differentiation Frontier”
In a proprietary QYSearch analysis of 25 HMO research programs (2025-2026), 5 are developing complex sialylated HMOs (disialyllactose (DSL), sialyllacto-N-tetraose (LST a, LST b, LST c), sialyllacto-N-neotetraose (LST d), fucosyl-sialyllactose). Higher bioactivity (anti-adhesive, immunomodulatory), closer to human milk composition (more complex HMO profile). However, significantly higher production cost (>$1,000/kg, multi-step fermentation, multiple enzyme pathways). First applications: high-end medical foods (preterm infants, immunocompromised, oncology supportive care). Novonesis, Inbiose/dsm-firmenich, DSM have patents. No commercial production yet. Differentiation strategy for premium infant formula brands beyond 3‘-SL/6‘-SL parity.

Conclusion & Outlook
The sialylated human milk oligosaccharides (HMO) market is positioned for very high growth (16.5% CAGR 2026-2032), driven by China NHC approval for 3‘-SL (infant formula), Kyowa Hakko Bio‘s Thailand facility expansion (Asian supply), and transition from basic supplementation to specialized functional nutrition (high-purity, regulatory compliance, supply reliability). Infant formula dominates (70-75% of demand), 3‘-SL larger volume share (55-60%), 6‘-SL growing (differentiated benefits). Europe and North America mature markets with incumbents (Novonesis, Inbiose/dsm-firmenich, DSM). Japan (Kyowa Hakko) and China (Zhuhai Langjian, Shanghai HuicH) fastest-growing regional production hubs. Future growth will mainly come from infant nutrition and premium nutrition formulations (medical foods, enteral nutrition, cognitive supplements) that seek ingredients closer to human milk, together with broader approved food categories (adult functional foods) and geographies (Southeast Asia, India, Middle East, Latin America). At the same time, high purity requirements (>98% for infant formula), complex processing (fermentation titer, downstream recovery), long approval cycles (3-5 years per ingredient per region), cost pressure (target $80-150/kg bulk price), and a still-concentrated supply base (Novonesis, Inbiose/dsm-firmenich, DSM, Kyowa Hakko, Zhuhai Langjian, Shanghai HuicH) remain the main constraints. Overall, this segment is likely to expand through high-value, regulation-led, stepwise commercialization (new isomers, new applications, new geographies) rather than rapid mass adoption (commodity-like price erosion). Manufacturers investing in regulatory clearances (China NHC, Japan FOSHU, Korea MFDS, India FSSAI, Brazil ANVISA, Mexico COFEPRIS, GCC SFDA, South Africa), production cost reduction (higher fermentation titer, lower purification cost, process intensification), and complex sialylated HMO development (differentiation beyond 3‘-SL and 6‘-SL) will lead the market for infant formula, functional foods, and emerging medical nutrition applications.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp